Posted on

Psychedelic Therapy Appears to be as Effective as a Leading Antidepressant

Read the original article here. According to research published in the New England Journal of Medicine,The phase 2, double-blind, randomized, controlled trial compared psilocybin to the antidepressant medication escitalopram.

The researchers recruited 59 men and women between the ages of 18 and 80 years who suffered from moderate-to-severe depression for their 6-week trial. Thirty patients were randomly assigned to the psilocybin group, while the remaining 29 patients were assigned to the escitalopram group.

The researchers also found that patients in the escitalopram group were more likely to report side effects such as anxiety, dry mouth, sexual dysfunction, and reduced emotional responsiveness compared to those in the psilocybin group. Patients in the psilocybin group reported greater improvements in the ability to cry and feel compassion, intense emotion, and pleasure.

While the initial findings are encouraging, the study has some limitations.

The duration of treatment could also be a factor. SSRIs like escitalopram can take several weeks to start reducing symptoms. “Had the course of escitalopram been extended, it is possible that better efficacy would have been observed among the patients in the escitalopram group,” the researchers noted.

The Conclusion:

On the basis of the change in depression scores at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. 

Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants.

Posted on

Why Psychedelics are Attracting R&D as Potential Treatments

Psychedelic R&D

Read the original article here. Recently, psychedelic drugs have become an increasingly popular area of research and drug development. Psychedelics, also known as hallucinogens, which include a range of compounds – some extracted from plants or fungi and others made synthetically, that are able to induce hallucinations if administered in sufficient quantities. These drugs are being evaluated in a range of serious neuropsychiatric and neurodegenerative disorders, including major depressive disorder (MDD), bipolar and anxiety disorders such as post-traumatic stress disorder (PTSD), as well as Alzheimer’s and Parkinson’s disease.

Much of this research started with ketamine, following some really promising clinical trials conducted roughly five years ago. Since then, the field has expanded beyond ketamine into other compounds, such as those developing and testing based on tryptamines. Tryptamines are natural compounds or designer drugs that originate from the decarboxylation of tryptophan and produce hallucinations through agonism of the (5-HT) 2α serotonin receptors. It is thought that their anti-depressive and anti-anxiety effects are mediated through the same pathway.

What does this mean?

Because tryptamines target specific receptors, they should deliver the same therapeutic benefit – restructuring the serotonergic synaptic processes within the brain – without the debilitating withdrawal effects seen with SSRIs. Dr. Mathew McMurray of Miami University says, “Since they target a specific receptor, instead of globally increasing serotonin throughout the brain, they are a potentially more targeted treatment for these disorders, reducing side effects such as serotonin syndrome. Another benefit is that they are naturally derived, not synthetic.”

In fact, Dr McMurray said that recent pre-clinical data from their lab suggests that a single dose of the tryptamine compounds they are developing may be effective in many people, where a typical SSRI like Prozac takes 15 to 20 days of treatment to reach early therapeutic efficacy. “Obviously, that is a much better clinical scenario because you may not have to keep treating people over and over; instead you could treat them once and send them on their way,” he said.

Because governments around the world have effectively been shutting down research or making it very difficult to perform for the last 70 years, we do not know as much about these classes of drugs as we would have otherwise. Essentially, we are at the early stages, which is exciting because there have been  many new discoveries since starting to research these compounds.


Posted on Leave a comment

Hamilton Morris Joins Advisory Board for Mind Cure | Canadian Mental Health Company

Image from

Read the original article here. Hamilton Morris is a trusted resource for millions worldwide as a psychoactive substances’ expert, who is at the forefront of the psychedelic movement. He’s a chemist, filmmaker, and science journalist. He is also the director of the award-winning documentary series Hamilton’s Pharmacopeia in which he explores the chemistry and traditions surrounding psychoactive drugs. 

Hamilton attended the University of Chicago and The New School in New York City, where he studied anthropology and science. He frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia. His research has allowed him to study psychoactive plants, fungi, and chemicals as well as the culture that surrounds them.

In his role as advisor, Mr. Morris will bring his renowned scientific and anthropological approach to Mind Cure, and in so doing will support the team in advising on new product candidate opportunities and their merits. Mr. Morris has been an active member of the scientific community during the psychedelic renaissance and is well respected for both his novel and disciplined, science-first position in its advancement.

Hamilton said, “The potential of psychedelics and new medicines to treat mental illness is significant,” and continued, “As a researcher and journalist, my work is always driven by science. I look forward to working with the team at Mind Cure as they research and discover new products to treat mental health.”

With Hamilton, Mind Cure intends to further its investigation into new product candidates and treatments which are effective in treating mental health. These new product candidates range from nootropics to psychoactive products and psychedelic substances.

Mind Cure’s mission is to identify, develop and commercialize products that enhance mental health and wellness, ease suffering and increase productivity. Their website says they were, “formed as a response to a world suffering from mental health crisis and in urgent need of effective treatments.

The question remains whether or not the people who are suffering actually want or can even afford these new treatment options. Time will tell, but it is nice to see mental health companies taking on advisors who are pioneers in the industry. 

Posted on Leave a comment

Mindleap Health | New Mental Health App With Psychedelic Integration

MindLeap Health article

Read the original article here. On September 30th, Mindleap is launching its mental health platform app for IOS and Android. According to the article, “Starting with psychedelic integration, the Mindleap platform will bring mental health specialists online, enabling a new era of digital mental health and wellness.” The company has also said they will be bringing on more mental health specialists later this year to address addiction, drug harm reduction and holistic wellness.

 Mindleap says its specialists are able to offer more personalized support all while providing end-users with the tools needed to track their progress and take control of their mental health. By tracking your mental health over time, they’ll be able to quantify your progress so you can be honest with yourself about how you’re doing. The Mindleap platform said it will provide a comprehensive space for users to actively engage with specialists starting with aftercare for therapeutic psychedelic use.

The article also notes, “Integration specialists help clients through a systematic process that can turn their psychedelic experience into something practical – this can include making sense of unique images or ideas that came to mind during a psychedelic experience, as well as setting new goals, habits and behaviors that can help to improve a person’s life.”

But how much will this all cost? Answer, we don’t yet know. Specialists will be able to choose their hours and prices, so they will vary. So far we know that you can schedule secure video calls once you’ve found a specialist you want to work with.

Sessions can last 20, 40, or 60 minutes, and many specialists offer a free 15-minute introductory session to determine if you are a good fit for one another. During video sessions, you have the option to share the data you’ve recorded on yourself with your specialist. Note that specialists can only see this data while you share it with them, and cannot save it.

Mindleap’s software development team has built the platform to meet all HIPAA guidelines by implementing secure electronic access to health data and remains in compliance with privacy regulations and best practices. The company said it has strict policies around how data is handled and stored; all data is encrypted in-transit and at-rest, and specialists are not permitted to save their clients’ data.

Their proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every person. With a unique combination of video calling and mood, emotion, and behavior monitoring, the Mindleap app may provide a comprehensive space for people to actively engage with specialists and enact change in their lives.

Lastly, Mindleap says it does not encourage people to spend time on their phones while taking psychedelic substances, and does not facilitate psychedelic use via the platform, but acknowledges a need for people to connect with trained professionals who can help them discuss and understand their individual psychedelic experiences.

Posted on Leave a comment

Ann Arbor City Council Votes 11-0 to Decriminalize Entheogenic Plants

decrim ann arbor
Picture from,_Michigan

Read the original article here.  Ann Arbor City Council voted unanimously Monday night, Sept. 21, in favor of a resolution declaring it’s the city’s lowest law enforcement priority to investigate and arrest anyone for planting, cultivating, purchasing, transporting, distributing, engaging in practices with or possessing entheogenic plants or plant compounds.

The resolution does not authorize or enable the commission of any crimes, council members said, and any significant violation of state or federal law or any use of entheogenic plants that poses a threat to public health, safety and welfare still could result in city law enforcement involvement.

Decriminalize Nature Ann Arbor, or DNA2,   has been lobbying city officials to take up the issue. Checkout their website here

 DNA2’s mission is “To improve human health and societal well-being by decriminalizing and expanding access to entheogenic plants and fungi through political and community education and advocacy.Their purpose is to decriminalize entheogenic plants, restore our root connection to nature, and improve human health, hope, and well-being.

Why should we decriminalize entheogenic plants you ask? DNA2 has an answer for that, read all 10 here. The very first argument is for American liberty and personal freedom. According to their website, “Human beings and American citizens have an unalienable natural right to use plants of their choice. Prosecution for possession of natural plants shall become the lowest law enforcement priority.”


Posted on Leave a comment

Taking a Look at Compass Pathways | A Synthetic Psilocybin Company |

Picture from

Read the the original article here. According to their website, Compass Pathways is a UK based company that “thinks differently about mental health”. They have a patent on a synthetic version of Psilocybin called COMP360 and are investigating the effectiveness of psilocybin therapy. 

Compass founders experienced the painful effects depression within their own family. They were soon motivated to find a new approach to mental health medicine. This includes psilocybin therapy sessions, which are currently undergoing clinical trials in Europe and America. They have a vision to relieve the overstretched mental health care system by developing new therapies for a  world of mental wellbeing.

Next, we will look at their values of being Compassion, Bold, Rigorous, and Inclusive.

Compassion – People suffering with mental health challenges should have options. Patients inspire them every day to change mental health care systems that don’t work for everyone.

Bold – They do not accept the status quo in mental health care systems, therapies or perceptions. They believe a transformation is needed to reduce human suffering.

Rigorous – They are seeking answers to how novel therapies, like psilocybin therapy, may create new pathways to mental wellbeing. They’re basing every decision, and every hope, on meticulous evidence.

Inclusive – They believe in collaborating to find ways to accelerate innovation and access to new therapies for all.

Posted on Leave a comment

New Center for Psychedelic Science and Education Launched by UC Berkeley

Neuroscientist Michael Silver
Neuroscientist Michael Silver, inaugural director of the UC Berkeley Center for the Science of Psychedelics. (Photo by Elena Zhukova)

Read the original article here. With $1.25 million in seed funding from an anonymous donor, the new UC Berkeley Center for the Science of Psychedelics will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.

Research at the new center will complement ongoing clinical studies at other institutions — such as Johns Hopkins University in Maryland and Imperial College London — that are integrating psilocybin and other psychedelic compounds with psychotherapy to treat mental disorders, such as anxiety, depression, post-traumatic stress disorder and substance abuse.

The centers inaugural director, Michael Silver, said “This is a pivotal time in history for a discussion about psychedelics and under what circumstances they should be used,” he said. “This has obviously been a very polarizing topic, but I think people’s minds are changing.”

One unique aspect of the new center is its emphasis on public education. It will produce a website offering rigorously vetted original and curated content covering scientific, political, business and cultural developments in psychedelics, Pollan said.

This program will eventually train guides, also known as facilitators, in the cultural, contemplative and spiritual care dimensions of psychedelics, working in partnership with the UC Berkeley Center for the Science of Psychedelics research studies. Given the rapidly growing number of psychedelic research studies, there are not enough trained facilitators to meet the demand, the center’s founders said.

At the center, researchers will focus on the use of these ancient compounds to explore the unplumbed depths of the mind and to shed light on how these molecules can improve mental health.

Posted on Leave a comment

Hopkins Starts Clinical Trial to Study Use of Psilocybin Mushrooms

By SALMA ABDEL-AZIM | September 10, 2020

Read the original article here. The study, led by researchers at Johns Hopkins, was announced on August 12 and hopes to survey people around the world to create a registry of information about psilocybin usage and resulting experiences. According to the CPCR recruitment site, the study aims to attract people who intend to use psilocybin mushrooms in the next six months. 

The participants will complete five surveys at varying periods before and after their usage of psilocybin. The study hopes to survey over 1000 people worldwide.

This isn’t the first time that Hopkins has studied the effects of psilocybin mushrooms. The CPCR became the first research group to gain approval to study the effects of psychedelics in 2000 and published a study that established the positive outcomes and safety of a single dose of psilocybin. 

Since the recent revival of psychedelic research, new studies have shown that these drugs, once seen as entirely detrimental to human health, may have positive effects for people who suffer from conditions including addiction and depression. 

Posted on

Howdy Y’all

Thank you so much for bearing with us while we went through a website redesign. We really appreciate all of you who still continue to come around and checkout our content. And speaking of content, keep checking back here for news, updates, and education information. We are so excited to go to the next level of service for you!

We will stay true to our vision – “Educate the world about the healing potential of multiple molecules and breaking the age-old stigma surrounding them.” by sharing informative and developing scientific studies. 


We will also stay true to our mission – “Provide premium sterile psilocybe cubensis spores to everyday researchers who want to increase their knowledge in microscopy.”, by permanently decreasing our prices without compromising quality.

We believe that everyone should be able to have the option to research these earthly specimens, if they so choose. Price shouldn’t be a hinderance to achieving lifelong satisfaction from a hobby.

We look forward to informing and serving you in the future! Mush Love